XQXingguang Qu

Xingguang Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xingguang Qu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Gaosheng Zhou

    The First Clinical Medical College of China Three Gorges University Yichang Hubei Province China

    2 shared publications
  • Yixun Wang

    The First College of Clinical Medical Science, China Three Gorges University, Yichang, China

    2 shared publications
  • Boya Gong

    Department of Critical Care Medicine, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, Hubei, 443000, People’s Republic of China

    1 shared publication
  • Can Zhuo

    Department of Spinal Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, Hubei, 443000, People’s Republic of China

    1 shared publication
  • Chao Lei

    The First College of Clinical Medical Science, China Three Gorges University, Yichang, China

    1 shared publication
  • Chao Lei

    Department of Critical Care Medicine, The First College of Clinical Medicine Science, China Three Gorges University affiliated Yichang Central People's Hospital, Yichang, Hubei, PR China

    1 shared publication

Latest Publications

  • Open Access

    Advances in Nano-Drug Delivery Systems for Osteosarcoma: From Targeting Strategies to Combating Lung Metastasis

    by Siyu Jia, Boya Gong, Haidan Chen, Yaohui Chen, Can Zhuo, Hongyan Wu, Xingguang Qu, Huili Cai

    Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children and adolescents, characterized by aggressive local invasion, early distant metastasis (predominantly lung metastasis), and poor prognosis. Conventional clinical regimens, mainly neoadjuvant chemotherapy combined with surgical resection, are limited by severe systemic toxicity, multidrug resistance, low tumor targeting, and unsatisfactory outcomes for metastatic OS, with the 5-year survival rate of metastatic patients remaining below 30%. Nanodrug delivery systems (NDDS) have emerged as a transformative strategy to address these bottlenecks by enabling targeted drug/gene delivery, controlled release, enhanced tumor accumulation, and reduced off-target effects. This review systematically summarizes the pathological characteristics and therapeutic dilemmas of OS, highlights recent advances in diverse NDDS including lipid nanoparticles, polymeric nanoparticles, carbon-based nanomaterials, extracellular vesicles, gold nanoparticles, and hydrogels for OS therapy, with a special focus on strategies to counteract lung metastasis. We further discuss the clinical translation challenges of NDDS in OS, especially pediatric-specific concerns, and propose future directions such as stimuli-responsive nanocarriers, biomimetic nanoparticles, combination therapy, and inhalable nanomedicines for pulmonary metastatic lesions. Overall, NDDS hold great promise to revolutionize OS treatment by improving therapeutic efficacy and safety, particularly in overcoming lung metastasis and chemoresistance.


  • Top Cited Papers
    Open Access

    Bidirectional Regulation of NLRP3 Inflammasome and Mitochondrial Quality Control in Sepsis: Mechanisms and Therapeutic Implications

    by Xiangxin Liao, Yixun Wang, Zhaohui Zhang, Xingguang Qu, Gaosheng Zhou

    Characterized by its capacity to induce organ failure, sepsis constitutes a life‐threatening pathological state with high incidence and mortality rates. Current treatments primarily focus on antimicrobial therapy and organ support, lacking direct interventions targeting the restoration of cellular or organelle function. Among these mechanisms, mitochondrial dysfunction and overactivation of the NLR family pyrin domain‐containing 3 (NLRP3) inflammasome stand out as key pathological hallmarks. As a classic inflammasome, the NLRP3 inflammasome, upon activation, drives cellular pyroptosis and massive release of inflammatory mediators. Beyond their role as cellular energy generators, mitochondria participate in the modulation of inflammatory responses and oxidative stress control. Mitochondrial quality control (MQC) serves as a prerequisite for the orderly performance of mitochondrial physiological functions. Disruption of MQC invariably results in mitochondrial dysfunction, triggering liberation of mitochondrial reactive oxygen species (mtROS) along with mitochondrial damage‐associated molecular patterns (mtDAMPs), which serve as direct triggers for NLRP3 inflammasome formation and stimulation. This process disrupts MQC, exacerbates mitochondrial dysfunction, and forms a mutually reinforcing “MQC imbalance‐NLRP3 overactivation” vicious cycle that drives disease progression. This review aims to: (1) systematically elucidate the complex bidirectional regulatory mechanisms between the NLRP3 inflammasome and MQC in the context of sepsis, (2) summarize the latest research progress on targeted intervention strategies based on this vicious cycle, and (3) discuss the challenges in clinical translation and future directions of these strategies.


  • Open Access

    Role of the endothelial cell glycocalyx in sepsis-induced acute kidney injury

    by Yixun Wang, Zhaohui Zhang, Xingguang Qu, Gaosheng Zhou

    Sepsis-induced acute kidney injury (S-AKI) is a common complication of sepsis. It occurs at high incidence and is associated with a high level of mortality in the intensive care unit (ICU). The pathophysiologic mechanisms underlying S-AKI are complex, and include renal vascular endothelial cell dysfunction. The endothelial glycocalyx (EG) is a polysaccharide/protein complex located on the cell membrane at the luminal surface of vascular endothelial cells that has anti-inflammatory, anti-thrombotic, and endothelial protective effects. Recent studies have shown that glycocalyx damage plays a causal role in S-AKI progression. In this review, we first describe the structure, location, and basic function of the EG. Second, we analyze the underlying mechanisms of EG degradation in sepsis and S-AKI. Finally, we provide a summary of the potential therapeutic strategies that target the EG.


  • Open Access

    Liver abscess and splenic infarction due to Yersinia pseudotuberculosis bloodstream infection: a case report

    by Yixun Wang, Yanni Xiang, Chao Lei, Xiaxia Zheng, Wen Wu, ZhaoHui Zhang, Xingguang Qu

    Yersinia pseudotuberculosis is an emerging zoonotic intestinal pathogen primarily transmitted through contaminated food and water. Infections caused by Yersinia pseudotuberculosis are typically self-limiting, often presenting as gastroenteritis or “pseudoappendicitis,” which is characterized by fever and abdominal pain. Although bloodstream infections with Yersinia pseudotuberculosis are rare, they can lead to multiple distant sites of infection, including abscesses in the liver, spleen, and kidneys, as well as in the hip and knee joints, particularly in individuals with underlying immunodeficiency. We report the case of a 40-year-old male patient who was admitted to the intensive care unit (ICU) with intermittent fever lasting for five days, followed by exacerbation of abdominal pain and distension one day after ingesting contaminated food. Upon admission, the patient exhibited severe hypotension, which rapidly progressed to signs of liver and kidney failure, ultimately leading to multiple organ dysfunction syndrome (MODS). Notably, abdominal computed tomography (CT) revealed evidence of a liver abscess and splenic infarction. The treatment regimen included fluid resuscitation, broad-spectrum antibiotics, vasopressors, continuous renal replacement therapy (CRRT), and plasma exchange. Blood cultures along with metagenomic next-generation sequencing (mNGS) confirmed an infection caused by Yersinia pseudotuberculosis. After 17 days in the ICU, the patient was transferred to the infectious disease department for an additional 14 days of treatment before being discharged. Three months post-discharge, follow-up visits indicated that the patient was in good health. To the best of our knowledge, this case represents a rare instance of multiple organ dysfunction syndrome (MODS), liver abscess, and splenic infarction resulting from Yersinia pseudotuberculosis infection. The identification of the pathogen was facilitated by blood culture and metagenomic next-generation sequencing (mNGS) of blood samples. The administration of broad-spectrum antibiotics, along with active support for organ function, ultimately contributed to the patient’s recovery. No applicable.


  • Open Access

    Intracarotid Infusion of Redox-Active Manganese Porphyrin, MnTnBuOE-2-PyP5+, following Reperfusion Improves Long-Term, 28-Day Post-Stroke Outcomes in Rats

    by Xuan Li, Weina Duan, Li Du, Dongmei Chu, Peng Wang, Zhong Yang, Xingguang Qu, Zhenxing Yang, Ines Batinic-Haberle, Ivan Spasojevic, et al.

    Endovascular mechanical thrombectomy, combined with a tissue plasminogen activator (t-PA), is efficacious as a standard care for qualifying ischemic stroke patients. However, > 50% of thrombectomy patients still have poor outcomes. Manganese porphyrins, commonly known as mimics of superoxide dismutases, are potent redox-active catalytic compounds that decrease oxidative/nitrosative stress and in turn decrease inflammatory responses, mitigating therefore the secondary injury of the ischemic brain. This study investigates the effect of intracarotid MnTnBuOE-2-PyP5+ (BMX-001) administration on long-term, 28-day post-stroke recovery in a clinically relevant setting. The 90 min of transient middle cerebral artery occlusion was performed in young, aged, male, female, and spontaneous hypertension rats. All physiological parameters, including blood pressure, blood gas, glucose, and temperature, were well controlled during ischemia. Either BMX-001 or a vehicle solution was infused through the carotid artery immediately after the removal of filament, mimicking endovascular thrombectomy, and was followed by 7 days of subcutaneous injection. Neurologic deficits and infarct volume were assessed at 28 days in a blinded manner. The effects of BMX-001 on the carotid arterial wall and blood–brain barrier permeability and its interaction with t-PA were assessed in normal rats. There were no intra-group differences in physiological variables. BMX-001-treated stroke rats regained body weight earlier, performed better in behavioral tests, and had smaller brain infarct size compared to the vehicle-treated group. No vascular wall damage and blood–brain barrier permeability changes were detected after the BMX-001 infusion. There was no drug interaction between BMX-001 and t-PA. Intracarotid BMX-001 infusion was safe, and it significantly improved stroke outcomes in rats. These findings indicate that BMX-001 is a candidate drug as an adjunct treatment for thrombectomy procedure to further improve the neurologic outcomes of thrombectomy patients. This study warrants further clinical investigation of BMX-001 as a new stroke therapy.